UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

The lancet oncology, 2022-01, Vol.23 (1), p.91-103

2022

Link zum Volltext

Verfügbarkeit prüfen

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Haematologica (Roma), 2023-03, Vol.108 (3), p.747

2023

Link zum Volltext

Verfügbarkeit prüfen

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

Rheumatology and therapy., 2020-03, Vol.7 (1), p.173-190

2020

Link zum Volltext

Verfügbarkeit prüfen

Raspberry Pi based interactive home automation system through E-mail

2014 International Conference on Reliability Optimization and Information Technology (ICROIT), 2014, p.277-280

2014

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

British journal of haematology, 2021-08, Vol.194 (4), p.690-700

2021

Link zum Volltext

Verfügbarkeit prüfen

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Blood, 2021-11, Vol.138 (Supplement 1), p.3878-3878

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2517-2517

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT036: Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT036-CT036

2021

Link zum Volltext

Verfügbarkeit prüfen

Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7548-7548

2021

Link zum Volltext

Verfügbarkeit prüfen

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2015-10, Vol.67 (10), p.2713-2722

2015

Link zum Volltext

Verfügbarkeit prüfen

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Blood, 2020-11, Vol.136 (Supplement 1), p.49-49

2020

Link zum Volltext

Verfügbarkeit prüfen

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

Blood, 2020-11, Vol.136 (Supplement 1), p.34-34

2020

Link zum Volltext

Verfügbarkeit prüfen

ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS7566-TPS7566

2019

Link zum Volltext

Verfügbarkeit prüfen

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Blood, 2021-11, Vol.138 (Supplement 1), p.649-649

2021

Link zum Volltext

Verfügbarkeit prüfen

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 2010-12, Vol.16 (23), p.5883-5891

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Blood, 2019-11, Vol.134 (Supplement_1), p.4093-4093

2019

Link zum Volltext

Verfügbarkeit prüfen

Sa1757 - Filgotinib Decreases Systemic and Mucosal Markers of Inflammation that are Associated with Endoscopic Improvement in Moderatly to Severely Active Crohn's Disease Patients

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-383-S-383

2018

Link zum Volltext

Verfügbarkeit prüfen

ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS7574-TPS7574

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT011-CT011

2023

Link zum Volltext

Verfügbarkeit prüfen

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7006-7006

2019

Link zum Volltext

Verfügbarkeit prüfen

Blockade of Interferon-[gamma] Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2015-10, Vol.67 (10), p.2713

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(54)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Humans
(11)
Life Sciences & Biomedicine
(11)
Male
(7)
Adult
(6)
Female
(6)
Middle Aged
(6)
Aged
(4)
Adolescent
(3)
Covid-19
(3)
Cytokines
(3)
Dose-Response Relationship, Drug
(3)
Engineering
(3)
Engineering, Electrical & Electronic
(3)
Hematology
(3)
Immunotherapy, Adoptive - Adverse Effects
(3)
Matlab
(3)
Technology
(3)
Young Adult
(3)
Antibodies, Monoclonal - Adverse Effects
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T‐NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL)

Raspberry Pi based interactive home automation system through E-mail

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL)

Abstract CT036: Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5

Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sa1757 - Filgotinib Decreases Systemic and Mucosal Markers of Inflammation that are Associated with Endoscopic Improvement in Moderatly to Severely Active Crohn's Disease Patients

Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL)

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)

Blockade of Interferon-[gamma] Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus

Suchergebnisse filtern